Natural killer (NK) cells and dendritic cells (DCs) have been shown to link the innate and adaptive immune systems. Likewise, a new innate cell subset, interferon-producing killer DCs (IKDCs), shares phenotypic and functional characteristics with both DCs and NK cells. Here, we show IKDCs play an essential role in the resolution of experimental autoimmune encephalomyelitis (EAE) upon treatment with the tolerizing agent, myelin oligodendrocyte glycoprotein (MOG), genetically fused to reovirus protein s1 (termed MOG-ps1). Activated IKDCs were recruited subsequent MOG-ps1 treatment of EAE, and disease resolution was abated upon NK1.1 cell depletion. These IKDCs were able to kill activated CD4 þ T cells and mature dendritic DCs, thus, contributing to EAE remission. In addition, IKDCs were responsible for MOG-ps1-mediated MOG-specific regulatory T cell recruitment to the CNS. 
Introduction
The maintenance of immunological self-tolerance is an active process, requiring the participation of both the adaptive and innate immune systems. However, most efforts in studying tolerance have focused on the adaptive rather than on the innate arm of immunity; consequently, the innate immune system's contribution to tolerance is not as well understood, particularly the role of NK cells on autoimmunity [1, 2] . This regulatory role is suggested by NK cells' ability to recognize and efficiently lyse activated T cells [3] , as well as act as a source of proinflammatory cytokines (IFN-g, GM-CSF, and TNF-a) and chemokines (CCL3, CCL4, and CCL5) [4] . Previous studies suggest the existence of a cell subset, termed bitypic NK/DCs [5] or NKDCs [6] , that shares phenotypical and functional features of both NK cells and DCs, despite the lack of an unambiguous set of phenotypic markers or a defined transcription factor.
More recently, a new cell subset, referred to as interferonproducing killer dendritic cells (IKDCs) [7, 8] , has been defined that shares features of both NK and DCs. Phenotypically, IKDCs have been originally described as CD3 , and MHC class II intermediate/high [7, 8] .
Functionally, IKDCs exhibit both cytolytic activity and MHC class II Ag presentation and therefore have been postulated as a bridge between the adaptive and innate arms of the immune system [7, 8] . It is still controversial whether IKDCs represent a separate lineage of DCs or merely a state of activation of NK cells, because poor Ag presentation capabilities by IKDCs is the heart of this debate. On one hand, IKDCs are able to present peptides to lymphocytes, but fail to process and present Ag to induce CD4 þ T cell proliferation [7, 9] , suggesting IKDCs are activated NK cells. This point of view is accepted by several groups [10e12] and supported by data showing human NK cells having limited Ag presentation capacity once activated [13] . On the other hand, IKDCs may originate from different lymphoid precursors [14] and can become bona fide Ag-presenting cells after encountering virus [15] or tumor cells [16, 17] , thus, supporting the notion of IKDCs as an independent cell lineage that truly shares phenotypic and functional features of NK cells and DCs.
Despite the recent focus on IKDCs' involvement in cancer [8, 15, 16] or viral infections [14] , little or no information is available on the role IKDCs play in inflammatory diseases. Here, we show for the first time, to our knowledge, that IKDCs contribute to the resolution of EAE. Stimulation of IKDCs is noted after mucosal administration of an auto-Ag, myelin oligodendrocyte glycoprotein, fused to reovirus type 3 protein sigma 1 (termed MOG-ps1). EAE is a T cell-dependent inflammatory disease principally mediated by IL-17 and is highly reproducible in susceptible rodent strains after immunization with TCR-reactive peptides and mimics some aspects of human multiple sclerosis (MS) [18] . Past efforts to induce modulation of autoimmunity by delivering auto-Ags have proven successful [19] ; however, such efforts are hampered by requiring large doses of Ag or repeated administration. To overcome these barriers, we have found single dose tolerance or immunotherapy can be accomplished by genetically fusing Ags [20] or auto-Ags [21, 22] to ps1. Mucosal ps1-delivered tolerogens have been found to induce IL-10-producing conventional regulatory T (T reg ) cells, as well as IL-4-producing Th2 cells, and when either subset is adoptively transferred, EAE could be reduced in an Ag-dependent fashion. Immunotherapy with MOG-ps1 requires MOG to be coupled to ps1, since ps1 alone, ps1 plus rMOG, or rMOG alone is unable to reverse EAE. Most notably, MOG-ps1 could reverse EAE clinical disease within 24 h of treatment [22] .
Although enhanced numbers of T reg cells have been found to infiltrate the CNS after MOG-ps1 treatment, understanding how this is accomplished within such a short time frame suggests possible innate cell involvement. In this context, the role of NK cells in the development of EAE has received considerable attention in recent years. NK1.1 þ cells have been shown to be protective during the course of EAE [23, 24] , since depletion of NK cells with an anti-NK1.1 mAb leads to EAE exacerbation [25, 26] , which could be due to their cytotoxic effects upon activated autoreactive CD4 þ T cells or DCs [3] . Consequently, an enrichment of NK cells in the CNS of diseased animals leads to amelioration of EAE [26] , while blocking the NK cell migration to the CNS exacerbates EAE [27, 28] . A protective effect of NK cells could also be attributed to the production of neuroprotective factors, such as the brain-derived neurotropic factor (BDNF) and neurotropin 3 (NT-3) [29] . Additionally, NK cell-produced IL-5 seems to play a protective role in MS [30] , and MS patients present lower levels of NK cells [31] , thus, suggesting a regulatory role for human NK cells. However, a consensus has yet to be reached over NK cells' role in the pathogenesis and development of EAE [32, 33] , since other groups have reported EAE amelioration after NK cell depletion [34] . Interestingly, an immunoregulatory subset of human NK cells based on their expression of CD56 and IL-2Rabg levels has been proposed [35] . Supporting this hypothesis, the reduction of the clinical MS relapse rate during pregnancy is associated with an increase in the CD56 bright (regulatory) subpopulation [36] .
However, a similar phenotype is still lacking in murine models [33] , and thus further studies are warranted in order to clarify the role of NK cells' involvement in EAE and other autoimmune diseases.
Herein we show IKDCs play a central role in the resolution of EAE following oral administration of MOG-ps1. MOG-ps1-induced an increase in the number of CD11c þ NK1.1 þ cells, but not conventional NK cells, in the periphery, as well as in the CNS of mice with EAE. CD11c þ NK1.1 þ cells were also able to lyse both DCs and activated CD4 þ T cells and, after MOG-ps1 treatment, induced a robust proliferation by transgenic OVA TCR CD4 þ T cells, thus, fulfilling the definition of IKDCs and effectively providing a link between the adaptive and innate immune systems. Moreover, IKDCS from MOG-ps1-treated mice showed a more activated phenotype than those from untreated controls, with an increase in the expression level of herpesvirus entry mediator (HVEM) and reduced expression of the inhibitory molecule NKG2A, allowing the lysis of CD4 þ T cells [37] . Interestingly, NKG2A þ IKDCs were responsible for producing IL-10, a cytokine shown to have a pivotal role in the amelioration of EAE after MOG-ps1 treatment [22] . In the absence of NK1. 
Materials and methods

Preparation of ps1, MOG-ps1, and MOG/GFP-ps1
MOG-ps1 and ps1 were prepared, as previously described [22] . To enable detection of MOG-ps1 binding, MOG-ps1 was genetically modified to incorporate GFP. Briefly, MOG was removed with EcoRI from the MOG-ps1 plasmid, and the remnant backbone was treated with calf intestine phosphatase and filled with a new EcoRISalI MOG and a SalI-EcoRI GFP fragments via a tripartite ligation. Recombinant clones were analyzed by DNA sequencing. The final construct for MOG/GFP-ps1 was transformed into Pichia pastoris via electroporation (ECM630 BTX Harvard apparatus). Protein expression in yeast and protein purification were performed, as previously described [22] . Proteins were assessed for purity and quality by Coomassie-stained polyacrylamide gels and by Western blot analysis, using an anti-His-tag mAb (Invitrogen, Carlsbad, CA).
Mice
Female 6e8 wk old C57BL/6 mice (Frederick Cancer Research Facility, National Cancer Institute, Frederick, MD) were used throughout the study. Breeding colonies of transgenic FoxP3-GFP, IL-10
, and OT-II mice (The Jackson Laboratory, Bar Harbor, ME) were maintained at Montana State University Animal Resources Center under pathogen-free conditions in individual ventilated cages under HEPA-filtered barrier conditions and were fed sterile food and water ad libitum. All animal care and procedures were in compliance with institutional policies for animal health and wellbeing. 
EAE induction and MOG-ps1-based therapies
In vivo NK cell depletion
Mice were i.v injected with 500 mg/ml of anti-NK1.1 mAb (PK136; Bio X Cell, West Lebanon, NH) at the time of or 7 days after EAE challenge. Mice were subsequently treated weekly i.p. until day 21 p.ch.
Isolation of mononuclear cells from CNS
Mice were perfused through the left cardiac ventricle with cold PBS. The forebrain and cerebellum were dissected, and the spinal cords (SCs) flushed out with PBS by hydrostatic pressure and digested with 10 ml HBSS containing 500 U/ml of collagenase (SigmaeAldrich) for 60e90 min at 37 C with shaking. The tissues were then homogenized in cold HBSS buffer (SigmaeAldrich) with the plunger of a syringe, filtered through a 70 mm cell strainer to obtain a single cell suspension, and centrifuged. Cell pellets from 4 to 5 mice were pooled, resuspended in 70% Percoll (SigmaeAldrich), and underlaid with 30% Percoll. Mononuclear cells were isolated from the 30/70 interphase after gradient density centrifugation, washed, and stained for flow cytometry.
Tetramer staining
Tetramer-based enrichment was performed similar to that previously described [41] . Briefly, CNS-infiltrating lymphocytes and splenocytes were first stained with MOG 42e55 -APC or OVA 329e337 -APC tetramer (NIH Tetramer Core Facility, Emory Univ., Atlanta, GA) for 1 h at room temperature in PBS containing 2% of FBS, 2% rat serum, and Fc block (BD Pharmingen). Cells were then stained with anti-APC magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer instructions and then passed over a magnetized column (Miltenyi Biotec) to separate bound and unbound fractions. The resulting fractions were then stained for extracellular markers and acquired fluorescence using a LSR-II flow cytometer (Becton Dickinson, San Jose, CA) and analyzed with Flow Jo software (Tree Star Inc., Ashland, OR).
Cytokine ELISAs
Spleens were removed 18e21 days after EAE induction from PBS-and MOG-ps1-treated mice. Bead-isolated CD25
þ T cells (>95% purity) were cultured for 4 days in the presence of 1:1 ratio of T cell-depleted splenic feeder cells with or without MOG 35e55 restimulation. Capture ELISA was employed to quantify the levels of IFN-g, IL-10, IL-17, and TGF-b, as previously described [22] .
Characterization and isolation of IKDCs
Splenic and lymph node (LN) cells including mesenteric LNs (MLNs) and head and neck LNs (HNLNs) were stained with biotinylated or fluorochrome-conjugated mAbs against B220 (clone RA3-6B2), CD1d (1B1), CD3 (145-2C11), CD25 (PC61), CD5 (53-7. 3), CD11c (HL3), and CD49b (Ha1/29), all from BD Pharmingen. CD4 (GK1.5), CD107a (1D4B), NKG2D (clone C7), and TRAIL (N2B2) mAbs were obtained from Biolegend (San Diego, CA). NK1.1 (PK136), NKG2A (16A11), HVEM (LH1), BTLA (8F4), MHC-II (M5/114.15.2), and CD11b (M1/70) mAbs were obtained from eBioscience; anti-PD-L1 mAb was from Serotec; and anti-LIGHT mAb was from R & D Systems. Intracellular staining for FoxP3, IFN-g, granzyme B, and IL-10 was accomplished using FITC-, PECy5-, or PE-labeled mAbs (eBioscience), and PE-or APC-anti-IFN-g or -anti IL-10 mAbs (BD Pharmingen). Cells were acquired using a LSR-II flow cytometer (Becton Dickinson) and analyzed with Flow Jo software (Tree Star Inc.). Cell-sorting was accomplished using a FACSAria (Becton Dickinson), as previously described [16] . Briefly, spleens and LNs were stained for CD3, CD11c, B220, MHC class II, CD11b, and NK1.1, and three different populations were sorted based on the expression of CD11c, NK1.1, and MHC class II. IKDCs were confirmed to be B220 þ and CD3 À . Cell purity exceeded 95%.
MOG/GFP-ps1 binding assays
Splenic cells from naïve or EAE mice were incubated at 4 C with 20 mg/ml of MOG/GFP-ps1 for 30 min, washed, and stained with mAbs to NK1.1 (clone PK136, eBioscience); CD11c (HL3, BD Pharmingen); B220 (RA3-6B2, BD Pharmingen); and HVEM (LH1, eBioscience) for another 20 min before being analyzed by flow cytometry.
Adoptive transfer
C57BL/6 mice were challenged with MOG 35e55 , as described above, and 15 days later, they were orally treated with 50 mg of MOG-ps1. Twenty-four hours later, spleens and LNs were combined and sorted, as indicated above. 
Proliferation assay
Briefly, 1 Â 2.12.
51
Chromium release assay
Cytotoxic assays were performed using DCs, CD4 þ T cells, or YAC-1 lymphoma cells (ATCC) as target cells. Briefly, 1 Â 10 6 target cells were incubated with 50 mCi of 51 Cr for 2 h at 37 C. Labeled cells were washed three times and then incubated with varying numbers of effector cells. For concanamycin A (CMA; Wako Bioproducts, Richmond, VA) treatment, 100 nM of CMA was added to desired wells. After 4 h incubation, 100 ml of each supernatant was harvested and radioactivity counted using a Beckman LS 6500 scintillation counter. Specific lysis was calculated by measuring the level of released 51 Cr from target cells corrected for spontaneous release/total 51 Cr release obtained by detergent (5% Triton X-100) lysis Â 100. Spontaneous lysis was measured from wells containing only labeled target cell [42] .
Statistical analysis
The ANOVA followed by posthoc Tukey test was applied to show differences in clinical scores in treated versus PBS mice. The student t test was used to evaluate the differences between percentages of positive cells between groups, and p-values <0.05 are indicated.
Results
MOG-ps1 abates EAE, and this therapeutic effect is abrogated upon NK1.1 mAb depletion
Mucosal application of the fusion protein, MOG-ps1, is effective against EAE in both prophylactic and therapeutic regimens. In fact, a single oral dose at the peak of disease resulted in significant 3-fold reduction in clinical scores within 24 h after treatment (Fig. 1A) . This resolution in EAE was accompanied by 3-fold increase in the number of NK1.1 þ cells in the spleens of treated mice (Fig. 1B) . To investigate further if MOG-ps1's protective effect was mediated by NK1.1 þ cells, mice were treated with a depleting PK136 mAb [24] , starting at 0 or 7 days after EAE induction (Fig. 1C) . Mice continued to receive weekly PK136 mAb treatments until day 21 p.ch, and NK1.1 þ cell depletion significantly augmented EAE for either treatment. Furthermore, MOG-ps1's protective effect was abated in mice depleted of their NK1.1 þ cells (Fig. 1D) . These data confirmed previous reports that highlighted the relevance of NK cells for EAE clearance [25, 26] and indicated MOG-ps1's clinical benefits were, at least partially, dependent on NK1.1 þ cells.
NK1.1 cell depletion abrogates MOG-ps1-mediated recruitment of FoxP3 þ T reg cells
Confirming our previous finding that MOG-ps1 treatment induced an up-regulation in the number of FoxP3 þ T reg cells in the spleens of treated mice ( Fig. 1E and F; [22] ), we questioned whether this increase was NK cell-dependent. Mice with EAE were NK1.1 mAb-depleted at the peak of disease (day 18) and, on day 20, were treated with MOG-ps1 or PBS. Mice previously treated with the depleting mAb showed a reduced number of FoxP3 (Fig. 1G) , while there was no effect on the number of T reg cells on the spleens (Supplementary Fig. S1 ). Moreover, 
CNS-infiltrating BM-derived cells showed a significantly lower percentage of FoxP3
þ T reg cells in GFP-FoxP3 reporter mice depleted of NK1.1 cells when compared with PBS-treated mice (Fig. 1H) , further implicating the significance for NK1.1 þ cells or their subsets in T reg cell recruitment.
Induced T reg cells are MOG-specific
Since conventional staining for MOG class II tetramers fails to detect low avidity Ag-specific CD4 þ T cells [43] , a cell enrichment step [41] was performed to enable detection of MOGspecific T reg cells. Splenocytes from EAE mice (day 15 p.ch, score 1e2) were stained with OVA 329e337 or MOG 42e55 tetramers prior to magnetic purification, and only the (column) bound fraction was positive for MOG 42e55 tetramer training ( Fig. 2A) . Subsequent analysis of splenocytes and CNS-infiltrating lymphocytes from severely sick (day 18, score 3e4) FoxP3-GFP reporter mice, showed the majority of CNS-infiltrating FoxP3 þ CD4 þ T cells in the bound fraction being tetramerspecific (Fig. 2BeC) , as opposed to CD8 þ T cells (data not shown). Thus, MOG-ps1 treatment enhanced the absolute number of tetramer-specific CNS-infiltrating T reg cells (Fig. 2C) . Moreover, most of the FoxP3 þ tetramer-specific SC-infiltrating lymphocytes appeared activated since these were CD69 þ (Fig. 2D) , unlike naive tetramer-negative CD25 À CD4 þ T cells (Fig. 2D) . Thus, this analysis demonstrates MOG-ps1 treatment enhances the recruitment of MOG-specific T reg cells into the CNS.
To determine the responsible cytokines induced by MOG-ps1, cytokine analyses were performed on purified splenic CD25 À CD4 þ and CD25 þ CD4 þ T cells isolated at the peak of the clinical EAE (around day 20 p.ch) from mice treated with MOG-ps1 or PBS 24 h earlier. T reg cells from MOG-ps1-treated mice showed significant elevations in IL-10 when compared to T reg cells from diseased PBS-treated mice (p < 0.01) with concomitant reductions in IFN-g and IL-17 (p < 0.01; Fig. 2E ). There were no significant changes in TGF-b production (Fig. 2E) . These results show MOG-psstimulated T reg cells protect via IL-10 with concomitant inhibition of IL-17 and IFN-g in a MOG-specific fashion. Fig. 2 . MOG-ps1 treatment increases the number of MOG-specific T reg cells. A. Splenocytes from C57BL/6 EAE mice were incubated with APC-OVA 329e337 (upper panels) or MOG 42e55 tetramer (lower panels) and then reacted with magnetic anti-APC-beads. Magnetically bound (right panels) and unbound cell fractions (left panels) were then stained for CD4, CD11b, and CD45. A representative experiment of 3 is shown. B. Spleens and CNS-infiltrating lymphocytes from GFP-FoxP3 reporter mice were isolated, stained with APCeMOG tetramer, and again divided into bound and unbound cell fractions. Histograms representing tetramer staining for both fractions are shown. C. Absolute number of MOGspecific T reg cells in the bound fraction of indicated groups is shown. *p < 0.05 versus PBS-treated mice. D. SC-infiltrating lymphocytes were purified from GFP-FoxP3 EAE mice and separated into MOG-tetramer bound and unbound fractions. Cells were then stained for CD4, CD11b, CD45, and CD69, and the percentage of CD69 þ tetramer-specific cells is shown for FoxP3 þ CD4 þ and FoxP3 À CD4 þ T cells in the bound fraction. E. CD25 þ CD4 þ and CD25 À CD4 þ T cells were purified from PBS-or MOG-ps1-treated mice 15 days after EAE induction, and were restimulated in vitro with MOG 35e55 in the presence of irradiated APCs. Cytokine levels (mean AE SEM from triplicate cultures) in culture supernatants were measured by cytokine-specific ELISAs 4 days after culture, and values are corrected for cytokine levels produced by unstimulated cells. *p < 0.05 versus PBS-treated mice. (Fig. 3A) . This population of cells expressed high levels of surface B220, MHC class II, and CD49b (Fig. 3A) , as others have found [7, 8] . Stimulation with MOG 35e55 showed these cells were IFN-g þ (Fig. 3A) , again, in concordance with these original studies. Given that MOG-ps1 treatment enhanced CD11c þ NK1.1 þ cells in diseased mice, we queried if MOG-ps1 treatment in the absence of EAE could induce CD11c
MOG-
þ cells in naïve mice. While naïve mice showed almost no CD11c þ NK1.1 þ cells, oral MOG-ps1 treatment augmented the presence of these cells in spleens and MLNs (Fig. 3B) (Fig. 3B) , while w1.0% of CD45 Hi CD11b þ BM-derived cells infiltrating the CNS were CD11c
þ cells versus w0.3% found in the PBS-treated EAE mice (Fig. 3C) . A modest increase in the percentage of CD11c
þ in the bone marrow of EAE versus naive mice (p < 0.05) was also found, although MOG-ps1 intervention failed to further increase this percentage ( Supplementary Fig. S2 ). 
NK1.1
þ cells expressed elevated levels of both CD80 and CD86 in spleens (Fig. 4A , left panels) and MLNs (Fig. 4A, right   panels (Fig. 4C) . Although MOG-ps1 treatment appeared to have no effect on the expression of the stimulatory molecule, NKG2D, CNS-infiltrating CD11c
þ cells in MOG-ps1-treated mice showed reduced expression of the inhibitory molecule, NKG2A (Fig. 4D) . However, since MOG-ps1-treated animals showed increased numbers of SC-infiltrating IKDCs, the total number of NKG2A
þ IKDCs was greater in MOG-ps1-treated than PBS-treated mice (Fig. 4D) (Fig. 4E) . After MOG-ps1 treatment, IL-10 production by NK1.1 þ cells was restricted to the NKG2A þ subset (Fig. 4F ). þ T cells and mature DCs (Fig. 5A ). Supporting this notion for IKDCs, their cytolytic activity was inhibited by >50% in the presence of concanamycin A (CMA), indicating their mechanism of killing is perforin-dependent [44] (Fig. 5B) .
To assess their capacity as Ag-presenting cells, CD11c
.1 þ cells were isolated from naive mice, mice just starting to show clinical symptoms of EAE (day 12, score 1), or from severely sick mice (day 21, score 3). Subsequently, the individual subsets were pulsed with OVA or OVA 323e339 to activate OT-II CD4 þ T cells. Although CD11c þ NK1.1 þ cells were able to present OVA 323e339 peptide, they failed to induce strong OT-II cell proliferation when pulsed with intact OVA (Fig. 5C ), unlike conventional DCs. However, the previously observed up-regulation of MHC class II molecules after MOG-ps1 treatment (Fig. 4B ) prompted us to investigate whether MOG-ps1 treatment had any effect on their ability to process and present Ag. Indeed, when the CD11c þ NK1.1 þ cells were incubated with OVA protein in the presence of MOG-ps1, they were able to stimulate the proliferation of OT-II CD4 þ T cells (Fig. 5D) , albeit not as efficiently as conventional DCs isolated from the same mice, thus, fulfilling their functional definition as Ag-presenting cells. Similarly, treatment of CD11c þ NK1.1 þ cells with B16F1 melanoma cells prior to OVA incubation also enhanced specific CD4 þ T cell proliferation, consistent with that previously reported [17] . Thus, the observed CD11c
þ subset truly shares both phenotypical and functional characteristics of NK cells and DCs and consequently is considered IKDCs.
MOG-ps1 treatment up-regulates HVEM expression by NK1.1 þ cells
Since IKDCs were enhanced in the spleen and CNS following MOG-ps1 treatment of EAE mice, we queried if MOG-ps1 treatment had any impact upon the number of CNS-infiltrating IKDCs. Interestingly, while a significant proportion of NK1.1 þ cells were positive for the co-stimulatory molecule HVEM, CD4 þ T cells were mostly positive for the HVEM ligand, LIGHT (Fig. 6A) , while B220 þ B cells were positive for the co-inhibitory molecule BTLA (B and T lymphocyte attenuator; data not shown), another HVEM ligand [45] . Interestingly, B220 þ CD5 þ regulatory B cells, but not B220 þ CD5 À inflammatory B cells [46] , were also LIGHT þ (Fig. 6B ). Furthermore, a significant increase was found in the number of HVEM þ IKDCs (both in the SCs and spleens) of MOG-ps1-treated Fig. 6C and D) . A kinetic analysis of HVEM expression of splenic IKDCs following EAE induction showed a rapid upregulation of HVEM, peaking around day 14. Such up-regulation of HVEM levels was not evident in IL-10 À/À mice, although these mice showed aggravated disease (average maximum score 4.5 versus 2.5 in wt mice (data not shown), further suggesting the relevance of HVEM þ NK1.1 þ cells in the resolution of EAE (Fig. 6D) . Overall, these data suggest an important role for HVEM expression by IKDCs, either directly acting as an activator of IKDCs or indirectly as an inhibitor of BTLA/LIGHT þ CD4 þ T or B cells. Consequently, the observed up-regulation of HVEM by IKDCs after MOG-ps1 treatment may provide a rationale for the observed clinical improvement.
HVEM þ IKDCs bind MOG-ps1
To assess whether MOG-ps1 directly interacts with IKDCs, we took advantage of a MOG/GFP-ps1 construct to perform a cell binding study. Splenocytes from naïve mice, mice with EAE (day 21, score 2e2.5), or mice recovering from EAE (day 40, score 1) were incubated with MOG/GFP-ps1 or PBS. Interestingly, only HVEM (Fig. 7C) . Again, MOG-ps1 binding was restricted to the HVEM þ subpopulation (Fig. 7C) , further suggesting the importance of the HVEM þ IKDC population in the MOG-ps1 associated clinical resolution of EAE.
Adoptive transfer of IKDCs protects against EAE
To further investigate the role of IKDCs in EAE, a FACS-sorting strategy was optimized to allow isolation of IKDCs from NK cells and DCs from MOG-challenged mice (day 15 p.ch). CD11c þ NK1.1 (Fig. 8A) [15, 33] . As previously reported [17] , about a third of the CD11c (Fig. 8B) . Interestingly, the MHC class II Hi subset also expressed higher levels of CD80 than their MHC class II intermediate/low counterparts (Fig. 8B) . As expected, the vast majority of DCs was MHC class II high , while CD11c À NK1.1 þ (NK) cells were MHC class II-negative (Fig. 8C) . When FACS-sorted activated MHC class II high IKDCs versus unactivated IKDCs and were adoptively transferred into mice challenged with MOG 35e55 7 days earlier, only MHC class II Hi IKDCs were able to significantly reduce EAE (Fig. 8D) .
Interestingly, mice adoptively transferred with unactivated IKDCs showed slightly more severe disease than the PBS control group during the first 20 days of the disease, and in fact they failed to resolve EAE (Fig. 8D ). (Fig. 9A) , thus, providing a rationale for MOG-ps1's therapeutic effects. When IKDCs and NK cells were cultured with the NK target cell line YAC-1, a profound up-regulation in CD107a, PD-L1, and granzyme B, by the MHC class II Hi IKDCs, not NK cells, further suggested a critical role for IKDCs in EAE recovery ( Fig. 9B and C) . Interestingly, both PD-L1 and CD107a levels were much higher for IKDCs than on NK cells (Fig. 9C) . However, when IKDCs were cultured with YAC-1 cells in the presence of mAbs specific for either BTLA or HVEM, this upregulation was abolished, again suggesting the protective role of IKDCs was mediated by this HVEM/BTLA interaction (Fig. 9C) .
To assess whether activated MHC class II Hi IKDCs were responsible for Ag presentation, as shown above (Fig. 4D) were able to induce a strong proliferation of CD4 þ T cells (Fig. 9D) , suggesting that only activated IKDCs (NK1.1 þ CD11c þ MHC class II Hi ) show the effector function required for protection against EAE.
Discussion
MS is a neurodegenerative disease of the CNS that involves infiltration of activated inflammatory cells, damaging both myelin and axons, and is the most prevalent cause of paralysis in young adults [32] . EAE, a rodent model for MS, shares many of the same features [47] of this neurodegenerative disease and is T cell-mediated. Although MS has been studied for more than 150 years, an effective and safe therapy for MS remains elusive [48] . However, IFN-b1a treatment has proven to be therapeutic for MS, enhancing both the number and activity of T reg cells and the percentage of CD56 bright NK cells [32, 49] , a subset associated with clinical remissions [50] and reduced brain MRI lesions [51, 52] . However, up to 50% of patients do not respond to type I IFNs [53] .
Moreover, both EAE models and clinical trials have shown that IFN-b treatment reduces clinical symptoms in Th1 cell-driven disease, but worsens Th17 cell-induced disease by a mechanism that remains unclear [54, 55] . Altogether, the available data indicate the relevance of IFNs in MS and possibly the importance of these described IKDCs, a source of IFNs. Other therapies, such as glatiramer acetate [56, 57] or mAbs, Rituximab [58] , Daclizumab [59] and Alemtuzumab [60] , directed against CD20, CD25, and CD52, respectively, are currently under clinical investigation and have promising efficacy, although some safety concerns remain [48] . IKDCs resemble both NK cells and DCs and were originally described as CD11c [7, 8] . However, acceptance of this novel lymphoid subset as a specific entity has yet to be widely accepted, partially, because of its lack of a unique cell surface marker or a defined transcriptional factor. Consequently, reliance on shared phenotypic markers, as well as functional attributes, is required to characterize IKDCs. In this regard, IKDCs are found to exert potent anti-tumor activity through the secretion of IFN-g and direct killing of tumor cells. Although some controversy remains over their Ag presentation capacity (and if consequently these truly constitute a separate lineage of DCs or a mere state of activation of NK cells), recent data [17] indicate that at least a subset of IKDCs (the CD11b þ fraction) is licensed by tumor 35e55 restimulation, yet could also produce IL-10, a potent immunomodulatory cytokine. It has been previously reported that co-production of IFN-g and IL-10 by NK cells dampens inflammatory responses [61] , further implicating the relevance of these cells in EAE remission. In addition, CD11c þ NK1.1 þ cells were also able to efficiently lyse YAC-1 cells, suggesting these are NK cells, and also, albeit with a lower avidity, lyse activated CD4 þ T cells and mature DCs, as previously reported [3] . While reduced expression of the NK cell inhibitory molecule, NKG2A, was observed after MOG-ps1 treatment, the total number of NKG2A þ IKDCs in the CNS was markedly enhanced, and IL-10 production was limited to these NKG2A þ cells. Given these findings, it is possible that IKDC cytolytic and regulatory activities may contribute to resolving EAE.
Upon evaluating the activation status of IKDCs, a dramatic upregulation of HVEM was found after EAE induction, and these cells showed enhanced MOG-ps1 binding, suggesting a possible relationship between HVEM expression and the capacity of IKDCs to become responsive to MOG-ps1 treatment. HVEM belongs to the tumor necrosis factor receptor family and regulates host immune responses to various pathogens and autoimmune diseases upon interactions with one of several ligands. Aside from binding herpesvirus gD protein, HVEM is able to bind Ig superfamily members, BTLA and CD160, and TNF superfamily ligands, LIGHT and LTa [45] . Of these, HVEM interactions with BTLA and LIGHT are of especial interest, since LIGHT is expressed by the majority of CD4 þ T cells and regulatory B220 þ CD5 þ B cells [46] in our system, and virtually all of the B cells are positive for BTLA. Engagement of HVEM by trans interaction with BTLA or LIGHT has been reported to induce co-stimulatory signaling and promote cell survival via activation of NF-kB [62] and IFN-g production and to increase antitumor activity of NK cells [63] . On the other hand, HVEM signaling through BTLA leads to inactivation mediated by SH2 domaincontaining protein tyrosine phosphatases 1 and 2 [64] . Due to this dual capacity of delivering both co-stimulatory and inhibitory signals, HVEM is often considered a molecular switch of the immune system [45, 65] . In our case, expression of HVEM by IKDCs may lead to inactivation of BTLA-expressing CD4 þ T lymphocytes, as well as IKDC activation through interaction with LIGHT þ CD4 þ T cells or BTLA-expressing B cells. As previously suggested, cis interactions between double positive HVEM and BTLA IKDCs may also be occurring [rev. in 45] . A significant proportion of regulatory B220 þ CD5 þ B cells are also positive for LIGHT and therefore may be implicated in the activation of HVEM þ IKDCs. Additional studies are currently under way to further elucidate the complex role of HVEM/ BTLA/LIGHT in EAE.
This work also shows T reg cells play a critical role in the resolution of EAE following MOG-ps1 treatment, thus, confirming our previous findings. Analysis of the CNS-infiltrating T reg cells showed these to be MOG-specific following staining with MHC class II tetramers, and to be more activated evident by the increased numbers of CD69 þ T reg cells present in the CNS in MOG-ps1-treated mice than in EAE diseased mice. More importantly, this beneficial impact by MOG-ps1 is dependent on NK1.1 þ cells, since mice treated with a depleting anti-NK1.1 mAb failed to recruit T reg cells and resulted in no clinical improvement. One possible explanation for this finding is the loss of DCs via cytolysis by MOG-ps1-activated IKDCs, since cross-talk between DCs and T reg cells has been well established [66] . IKDCs express high levels of NKG2A, which is consistent with this hypothesis [67] . Alternatively, there could be direct interaction between NK and T reg cells through BTLA/ HVEM ligation or NK cell-dependent CCL22 secretion [68] . Additional studies are warranted to determine how cells interact to resolve autoimmunity.
MHC class II levels in conjunction with NK1.1 and CD11c have previously been considered the only unambiguous marker for IKDCs [15, 33] Interestingly, IKDCs also up-regulate the effector molecules granzyme B, CD107a, and PD-L1. During the last few years, PD-1/PD-L1 interaction has emerged as a critical regulator of EAE and other autoimmune diseases [39, 69] . The observed PD-L1 up-regulation may contribute to the clinical effect through the inhibition of PD-1 þ encephalitogenic CD4 þ T cells [69] . To the best of our knowledge, this is the first work in which IKDCs are demonstrated to be protective in autoimmune diseases, thus, opening the door to future clinical interventions. However, further studies are needed in order to unambiguously dissect all the multiple proposed mechanisms of action (IL-10 production, HVEM up-regulation, T reg cell recruitment, cytolytic activity, PD-1 ligation, and Ag presentation) and their relative clinical relevance. 
